ERBB2 and neoplasm: Compared with the control group, the group of 0.02 mg/kg tunicamycin, 10 mg/kg trastuzumab and the combination treatment inhibited tumor growth by 24.6%, 50.7% and 77.2% in MCF-7/HER2 xenograft, respectively (Figure 7A).